Group 1 - The company Zhejiang Oriental Gene Biological Products Co., Ltd. has approved a share repurchase plan to maintain company value and shareholder rights, with a maximum repurchase price of RMB 32.44 per share and a total repurchase amount between RMB 25 million and RMB 50 million [2][3] - As of July 31, 2025, the company has repurchased a total of 234,591 shares, accounting for 0.1164% of the total share capital, with a total payment of RMB 6.812262 million [3][4] Group 2 - The company and its subsidiaries have obtained several medical device registration certificates, enhancing its product series in the domestic inflammation indicator detection field and expanding the application of its flow cytometry technology platform [6][7] - The company has also achieved major product self-testing certifications in the United States, the United Kingdom, and Thailand, which will help expand its market presence in these key regions [7]

证券代码：688298 证券简称：东方生物 公告编号：2025-036 浙江东方基因生物制品股份有限公司 关于以集中竞价交易方式回购公司股份进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 浙江东方基因生物制品股份有限公司（以下简称"公司"）于 2025 年 6 月 26 日召开第三届董事会第十三次会议，审议通过了《关于以集中竞价交易方式回购 公司股份的方案》，同意公司以自有资金或自筹资金（含股票回购专项贷款资金等） 通过上海证券交易所交易系统以集中竞价交易方式回购公司已发行的部分人民币 普通股（A 股）股票，本次回购的股份将用于维护公司价值及股东权益，回购价格 不超过人民币 32.44 元/股（含），回购资金总额不低于人民币 2,500.00 万元（含）， 不超过人民币 5,000.00 万元（含），回购期限自董事会审议通过本次股份回购方案 之日起不超过 3 个月。本次回购的股份将在公司披露回购结果暨股份变动公告 12 个月后采用集中竞价交易方式出售，并在 3 年内完成出售。具体内容详见公司于 20 ...

证券代码：688298 证券简称：东方生物 公告编号：2025-037 浙江东方基因生物制品股份有限公司 关于自愿披露获得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 三、境外合作取得医疗器械注册证基本情况如下： | 产品名称 | 适用国家 及证书编 | 证书类 | 预期用途 | 有效期 | 持证 | | --- | --- | --- | --- | --- | --- | | | 号 | 型 | | | 公司 | | Healgen Rapid Check | | | 本产品拟用于直接从个体鼻 | | | | COVID-19/Flu A&B Antigen Test | 68-2-2-1-000 | 泰国医疗 | | 至 | 东方 | | 衡健新冠、甲乙流抗原联合检测 | | | 拭子标本中定性和快速鉴别 | | | | | 7059 | 器械证书 | | 2029/12/31 | 生物 | | 试剂（自测） | | | 检测新冠、甲乙流抗原。 | | | 四、对上市公司的影响 公司炎症标志物 ...

2024年1至12月份，东方生物的营业收入构成为：体外诊断行业占比97.99%，其他业务占比2.01%。 （文章来源：每日经济新闻） 东方生物（SH 688298，收盘价：28.95元）8月4日晚间发布公告称，截至2025年7月31日，公司通过上 海证券交易所系统以集中竞价交易方式回购公司股份累计达到约23.46万股，占公司总股本约2.02亿股的 比例为0.1164%，回购成交的最低价为28.3元/股，最高价为29.52元/股，支付金额约681.23万元人民币。 ...

Core Insights - The core viewpoint of the article highlights the significant revenue contribution of the in vitro diagnostics sector to Dongfang Biological's overall business, indicating a strong focus on this industry segment [1]. Company Overview - Dongfang Biological's revenue composition for the year 2024 is reported as 97.99% from the in vitro diagnostics industry and 2.01% from other business activities [1]. - The company announced on August 4 that it has obtained several medical device registration certificates through its subsidiaries, including the "Inflammatory Marker Test Kit" and has recently achieved overseas medical device registration for a respiratory panel test [3]. Industry Context - The in vitro diagnostics industry is a critical area for Dongfang Biological, as evidenced by its overwhelming revenue share, suggesting a robust market presence and potential for growth in this sector [1].

格隆汇8月4日丨东方生物(688298.SH)公布，截至2025年7月31日，公司通过上海证券交易所系统以集中 竞价交易方式回购公司股份累计达到23.4591万股，占公司总股本20,160.00万股的比例为0.1164%，回购 成交的最低价为28.30元/股，最高价为29.52元/股，支付金额681.2262万元人民币。 ...

Core Viewpoint - The company and its subsidiaries have obtained multiple medical device registration certificates, which will enhance product variety and facilitate market expansion, although the actual sales performance remains uncertain [1] Group 1: Product Registration - The company and its wholly-owned subsidiary, Shanghai Wanzijian Biotechnology, have received registration certificates for various medical devices, including inflammation marker detection kits and COVID-19/FluA&B antigen combined test kits [1] - The registration includes self-testing kits and rapid antigen tests for FluA&B, RSV, and Adenovirus [1] Group 2: Market Impact - The acquisition of these registration certificates is expected to enrich the company's product offerings, aiding in market expansion [1] - However, the actual sales performance will depend on product competitiveness and market sales capabilities, making it difficult to predict the impact on future operating performance [1]

金融界消息 截至2025年7月29日收盘，东方生物（688298）报收于29.21元，下跌0.17%，换手率 1.65%，成交量3.32万手，成交金额9665.67万元。 资金流向方面，今日主力资金净流出2182.66万元，占比成交额22.58%。其中，超大单净流出556.88万 元、占成交额5.76%，大单净流出1625.79万元、占成交额16.82%，中单净流出流入724.34万元、占成交 额7.49%，小单净流入1458.32万元、占成交额15.09%。 东方生物最新一期业绩显示，截至2025一季报，公司营业总收入1.92亿元、同比增长4.94%，归属净利 润11545.25万元，同比减少71.41%，扣非净利润11793.47万元，同比减少8.19%，流动比率4.042、速动 比率3.707、资产负债率14.11%。 通过天眼查大数据分析，浙江东方基因生物制品股份有限公司共对外投资了42家企业，参与招投标项目 118次，知识产权方面有商标信息152条，专利信息260条，此外企业还拥有行政许可116个。 来源：金融界 天眼查商业履历信息显示，浙江东方基因生物制品股份有限公司，成立于2005年，位于湖州市 ...

Group 1 - The fentanyl concept index declined by 0.88%, ranking among the top declines in the concept sector as of July 29 [1] - Within the fentanyl sector, companies such as Botao Bio, Enhua Pharmaceutical, and Wanfu Bio experienced significant declines, while three companies, including China National Pharmaceutical Modern, Lingrui Pharmaceutical, and Renfu Pharmaceutical, saw slight increases of 1.07%, 0.17%, and 0.09% respectively [1] Group 2 - The fentanyl concept sector experienced a net outflow of 80 million yuan in capital today, with six stocks seeing net outflows, and five stocks with outflows exceeding 10 million yuan [2] - Renfu Pharmaceutical had the highest net outflow of 18.1651 million yuan, followed by Dongfang Bio, Enhua Pharmaceutical, and Wanfu Bio with net outflows of 16.8542 million yuan, 16.6752 million yuan, and 15.9620 million yuan respectively [2] - The top net inflow stocks in the fentanyl concept sector included China National Pharmaceutical Modern and China National Pharmaceutical, with net inflows of 9.5225 million yuan and 1.2608 million yuan respectively [2]

Summary of Key Points Core Viewpoint - The company, Zhejiang Oriental Gene Biological Products Co., Ltd., is actively engaging in a share buyback program to maintain its value and protect shareholder interests, with a planned expenditure of between 25 million to 50 million RMB [1]. Trading Information - As of July 25, 2025, the company's stock closed at 29.39 RMB, down 0.64%, with a turnover rate of 2.41% and a trading volume of 48,600 shares, resulting in a total transaction amount of 142 million RMB [1]. - On the same day, the net outflow of funds from major investors was 9.49 million RMB, accounting for 6.67% of the total transaction amount, while retail investors saw a net inflow of 10.96 million RMB, representing 7.7% of the total transaction amount [1][3]. Company Announcements - The company announced a share buyback plan on June 26, 2025, with the buyback period set from June 26, 2025, to September 25, 2025. The buyback aims to acquire shares worth between 25 million to 50 million RMB [1]. - As of July 25, 2025, the company has repurchased 9,555 shares through the Shanghai Stock Exchange, which is 0.0047% of the total share capital of 20,160,000 shares, at a price range of 29.20 to 29.25 RMB per share, totaling 279,336 RMB [1].